Intrathecal pemetrexed

Phase 2Small molecule

Intrathecal pemetrexed is one of 76 small molecule programs targeting Leptomeningeal Metastasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leptomeningeal MetastasisRecruiting

Leptomeningeal MetastasesRecruiting

TreatmentNot yet recruiting

Brain MetastasesNot yet recruiting

Leptomeningeal MetastasisPreclinical

Recruiting

Leptomeningeal MetastasesPhase 2

Recruiting

TreatmentPhase 2

Not yet recruiting

Brain MetastasesPhase 2

Not yet recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Intrathecal pemetrexed

HHunan Province Tumor Hospital

Phase 2

1 2

Theo-Dur

Pfizer

Preclinical

1 3

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 4

Lamprene

Novartis

Preclinical

1 5

Emtriva

Gilead

Preclinical

1 6

Foscavir

CClinigen, Inc.

Preclinical

6 7

Reminyl

WWim Janssens

Preclinical

1 8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Sirturo

WWim Janssens

Preclinical

1 10

Clomid

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Leptomeningeal Metastases

NCT06440954

Q3 2028

PreclinicalRecruiting

Leptomeningeal Metastasis

NCT07751536

Q4 2028

Phase 2Not yet recruiting

Treatment

NCT06441045

Clinical

Trials by Indication[1]

Brain Metastases1 trial

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Not yet recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06497543·80 enrolled

Treatment1 trial

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06441045·112 enrolled

Leptomeningeal Metastases1 trial

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT06440954·220 enrolled

Leptomeningeal Metastasis1 trial

Dynamic Adaptive Radiotherapy for Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase: A Multicenter Randomized Controlled Trial Comparing Outcomes Between Proton Craniospinal Irradiation and Intrathecal Pemetrexed (DART-LM)

Recruiting·SShuanghu Yuan·Preclinical·NCT07751536·84 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Intrathecal pemetrexed. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intrathecal pemetrexed compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intrathecal pemetrexed. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hunan Province Tumor Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHunan Province Tumor Hospital

Intrathecal pemetrexed

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Q4 2028

Trials by Indication[1]

Brain Metastases1 trial

Treatment1 trial

Leptomeningeal Metastases1 trial

Leptomeningeal Metastasis1 trial

References

Drug Info

Quick Facts

Related News